Oral small molecule GLP-1 receptor agonist
HRS-7535 90 mg tablet once daily
HRS7535_PO_90MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.54 (0.01 to 39.07) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.48 (1.04 to 6.45) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.84 (0.11 to 5.89) | 0.63 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.74 (0.35 to 9.66) | 0.30 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.67 (0.09 to 28.13) | 0.49 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 11.20 (3.92 to 38.06) | 0.09 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.64 (2.61 to 28.02) | 0.20 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.48 (1.10 to 13.23) | 0.22 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.81 (0.05 to 12.70) | 0.48 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.19 (0.00 to 4.44) | 0.70 |
| Chronic kidney disease with diabetes | Serious adverse events | longest follow-up | Placebo | HR 1.68 (0.29 to 11.25) | 0.39 |
| Chronic kidney disease with diabetes | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.61 (0.08 to 26.36) | 0.59 |
| Chronic kidney disease with diabetes | Nausea | longest follow-up | Placebo | HR 10.53 (2.24 to 46.61) | 0.07 |
| Chronic kidney disease with diabetes | Vomiting | longest follow-up | Placebo | HR 7.24 (1.57 to 30.94) | 0.25 |
| Chronic kidney disease with diabetes | Diarrhea | longest follow-up | Placebo | HR 3.37 (0.67 to 16.67) | 0.37 |